Cardiff Oncology (CRDF) Amortization of Deferred Charges (2016 - 2017)
Cardiff Oncology (CRDF) has disclosed Amortization of Deferred Charges for 6 consecutive years, with -$70657.0 as the latest value for Q2 2017.
- Quarterly Amortization of Deferred Charges fell 5.95% to -$70657.0 in Q2 2017 from the year-ago period, while the trailing twelve-month figure was -$271124.0 through Jun 2017, down 306.55% year-over-year, with the annual reading at -$201037.0 for FY2016, N/A changed from the prior year.
- Amortization of Deferred Charges hit -$70657.0 in Q2 2017 for Cardiff Oncology, down from -$66119.0 in the prior quarter.
- In the past five years, Amortization of Deferred Charges ranged from a high of $2.3 million in Q3 2013 to a low of -$70657.0 in Q2 2017.
- Historically, Amortization of Deferred Charges has averaged $821557.3 across 4 years, with a median of $345539.5 in 2013.
- Biggest YoY gain for Amortization of Deferred Charges was 209.87% in 2013; the steepest drop was 67.73% in 2013.
- Year by year, Amortization of Deferred Charges stood at $2.3 million in 2013, then changed by 0.0% to $2.3 million in 2014, then tumbled by 102.88% to -$67659.0 in 2016, then dropped by 4.43% to -$70657.0 in 2017.
- Business Quant data shows Amortization of Deferred Charges for CRDF at -$70657.0 in Q2 2017, -$66119.0 in Q1 2017, and -$67659.0 in Q4 2016.